tbuckley/cabot-search huggingface dataset:
Stroger Hospital of Cook County (CCH) AIDS malignancy project: The CHAMP study—A 13-year, single institution retrospective study of cancers in patients infected with HIV.
Authors: S. Gupta, H. Poola, K. K. Batra, J. M. Orsi, S. Velinova, S. Jain, S. B. Sreenivasappa, M. C. Telfer, M. R. Mullane, A. L. French, P. G. Rubinstein
Journal: Journal of Clinical Oncology (2011)

1551 Background: CCH is the largest health provider for HIV patients in Chicago and has one of the largest HIV outpatient clinics in the United States, the Ruth M. Rothstein CORE Center (CC). Per year, over 5000 HIV + individuals are treated at the CC with over 500 HIV-infected individuals treated at CCH. Most studies of non-AIDS defining (NADC) and AIDS defining cancers (ADC) cover wide areas. Insights into the prevalence, type of cancer, and characteristics of HIV + cancer patients found in the inner city and underserved populations have been under represented in the literature. To this end, we examined all of the malignancies presenting to either the CC or CCH for the past 13 years. Methods: We identified via CCH, CC, and pharmacy databases all HIV infected patients with a cancer ICD9 codes from 1998-2010. HIV characteristics, cancer type, and patient demographics were confirmed by chart review. One-way Anova was used to show statistical significant between the prevalence among the different sub populations. Results: After initial screening, 404 cancers were confirmed, representing 21 malignancies. 56% were ADC, with 104 (25%) non-hodgkins lymphoma (NHL), 111(28%) Kaposi sarcoma, and 11(2.7%) cases of cervical cancer. Of the 104 NHL, the most common were DLBCL 61%, Burkitts (BL) 21%, and primary CNS lymphoma 7.6%. The most frequent NADC was anal cancer (n=30) and Hodgkin lymphoma (n=29). 70% of all cancers were stage III or above. HIV + patients at the CC were 71% African American (AA) and 19% Hispanic (Hsp) (compared to 26% and 23% in the Chicago population, respectively). In our study, AA represents 64% of all HIV cancers with Hsp and Caucasians 17% each. Though Caucasians with HIV and cancer in our cohort have the highest prevalence of cancer, 1.06%, vs. 0.69% AA vs. 0.60 Hsp (P< 0.001). The Male:Female ratio of all HIV malignancies in our cohort are 5.1:1. Conclusions: Our data show a race disparity isolated to AA compared to the general population, and a male predominance. Although the Caucasian-HIV population is the smallest, they have the highest cancer prevalence.
Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly with Imatinib Mesylate (STI571) and Chemotherapy.
Authors: Andre Delannoy, Véronique Lhéritier, Xavier Thomas, Sylvie Castaigne, Françoise Rigal-Huguet, Emmanuel Raffoux, Frederic Garban, Ollivier Legrand, Francis Witz, Viviane Dubruille, Pascal Turlure, Xavier Troussard, Martine Delain, Françoise Isnard, Diane Coso, Pascale Raby, Agnès Buzyn, Sylvie Caillères, Stéphane Darre, Bruno Lioure, Anne Sonet, Chrystele Bilhou-Nabera, Marie-Christine Bene, Elizabeth Macintyre, Eric Delabesse, Jean-Paul Vernant, Norbert Ifrah, Hervé Dombret, Patrice Berthaud, Denis Fière
Journal: Blood (2005)
Phase II trial of bolus 5-FU/l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant unresectable gastric cancer (HGCSG1502).
Authors: Tetsuhito Muranaka, Satoshi Yuki, Kentaro Sawada, Yasuyuki Kawamoto, Hiroshi Nakatsumi, Masayoshi Dazai, Hideyuki Hayashi, Michio Nakamura, Atsushi Ishiguro, Susumu Sogabe, Yoshimitsu Kobayashi, Takuto Miyagishima, Ichiro Iwanaga, Miki Tateyama, Kazuteru Hatanaka, Takashi Kato, Naoya Sakamoto, Yuh Sakata, Yoshito Komatsu
Journal: Journal of Clinical Oncology (2016)

TPS177 Background: S-1, oral fluorouracil agent compounding tegafur, 5-chloro-2, 4-dihydropyrimidine, and potassium oxonate for gastric cancer showed non-inferiority relative to a continuous infusion of fluorouracil in JCOG9912 trial. Similarly, in ISO-5FU10 trial, S-1 revealed non-inferiority effect compared with the treatment with bolus 5-FU/l-LV treatment. It is known that there is a different mechanism of anti-cancer effect between continuous 5-FU and bolus injection of 5-FU. Continuous infusion of 5-FU and oral fluorouracil inhibit DNA synthesis, however, bolus injection of 5-FU causes dysfunction of RNA in a concentration-dependent manner. So we considered bolus 5-FU/l-LV treatment might be useful for oral fluorouracil resistant patients with gastric cancer. Methods: This is a multi-centered single-arm prospective phase II study in Japanese patients with oral fluorouracil resistant gastric cancer. The key eligibility criteria are as follows: 1) Pathologically diagnosed gastric adenocarcinoma: 2) Unresectable advanced, metastatic, or recurrent disease; 3) resistance of S-1 or capecitabine; 4) resistance or intolerance of cisplatin or oxaliplatin, paclitaxel or docetaxel, and ramucirumab; 5) 20 years of age or older; 6) ECOG PS of 0, 1 or 2. Bolus 5-FU/l-LV regimen consists of l-LV 250mg/m 2 /2h iv and 5-FU 600mg/m 2 iv bolus given intravenously once weekly followed by 2-week rest period, within a 8-week cycle. The primary endpoint is progression free survival rate after 1cycle administration. And the secondary endpoints are response rate, disease control rate, overall survival, progression free survival, time to treatment failure, adverse events, dose intensity and QOL by EORTC QLQ-C30. This study is recruiting in Hokkaido Gastrointestinal Cancer Study Group and registered as UMIN000018882. Clinical trial information: UMIN000018882.
Patient and provider preferences: Treatment summary and survivorship care plans after hematopoietic cell transplant.
Authors: Elizabeth A Murphy, Navneet S. Majhail, Kevin Scott Baker, Beatrice Abetti, Balkrishna N. Jahagirdar, Naynesh Kamani, J. Douglas Rizzo, Wael Saber, Lizette Salazar, Barry Schatz, Karen Leslie Syrjala, John R. Wingard, Ellen M Denzen
Journal: Journal of Clinical Oncology (2016)

63 Background: There is a critical need to increase awareness of late complications and recommended preventive care among patients and providers and improve communication about long-term care. During transition back to community, care often becomes fragmented and insufficient to address survivors’ complex medical needs. A survivorship care plan (SCP) was developed using disease and hematopoietic cell transplant (HCT) data submitted to an outcomes registry. A treatment summary incorporates these data and identifies important treatment-related risk factors. The care plan uses these risk factors and long-term follow-up guidelines (Majhail et al, BBMT/BMT 2012) to provide personalized recommendations for preventive care. Study aims were to characterize patient-centered elements that will increase acceptability of the SCP. Methods: Phone focus groups (N = 12) were conducted for: 1) adult allogeneic patients &gt; 1 year post-HCT and their caregivers (3 groups, N = 22); 2) hematology/oncology and primary care physicians/mid-level providers (3 groups, N = 24); 3) HCT providers (2 groups, N = 14); and 4) HCT nurses/social workers (4 groups, N = 17). Transcripts were coded and analyzed for saturation of key themes. Coding reliability and validity were assessed (kappa &gt; .90). Results: Patients/caregivers reported challenges in accessing specialty care due to providers’ unfamiliarity with HCT and felt SCP should be more personalized with robust sections on psychosocial, sexual/mental health, and diet. Providers found the SCP markedly better than what they currently receive. Both patients and providers identified that SCP will facilitate appropriate post-HCT care. Similar themes were identified among the health professional groups, with the exception of screening and care for psychosocial issues more frequently mentioned by the nurses/social workers. Conclusions: Our study highlights the need for a personalized SCP tool to facilitate HCT survivorship care. Patient and provider feedback has been used to refine the SCP for which effectiveness is being assessed in a randomized, controlled trial. Engaging all stakeholder groups in this research helped to ensure patient-centeredness of the SCP.
Multimodality imaging and radiological-pathological analysis of ethiodized oil: Imaging biomarker of tumor necrosis after TACE?
Authors: Sampson K Kyere, Rafael Duran, Rüdiger E. Schernthaner, Samuel Greene, Ming De Lin, Jae Ho Sohn, Sonia Sahu, Laura D. Wood, Robert A Anders, Jean-Francois Geschwind
Journal: Journal of Clinical Oncology (2015)

TPS503 Background: In transarterial chemoembolization (TACE) for primary and metastatic liver malignancies ethiodized oil (Lipiodol) serves 3 roles: vehicle to deliver high concentration of the chemotherapeutic agent to the tumor, embolic agent to the tumor feeding artery and a contrast agent. The latter allows for intraprocedural visualization during drug delivery. Because of increased retention in liver tumors, Lipiodol can be visualized post-TACE for several weeks to months. Controversial preclinical and clinical data have been published about the role of Lipiodol as an imaging biomarker for treatment success after TACE. Here we investigate whether increased tumor Lipiodol deposition correlates with tumor response and survival using multimodality imaging and radiological/pathological correlation. Methods: This is a prospective phase 2, single center, IRB-approved study. Inclusion criteria include adult patients (Child-Pugh class of A or B and ECOG performance status of 0-2) with unresectable HCC with liver predominant disease or hepatic metastases from any solid tumor. Dynamic contrast-enhanced (DCE) MRI and CT of the liver and PET-CT were obtained before TACE. 24 hours after TACE, a noncontrast CT of the liver was obtained to quantify Lipiodol retention in the targeted tumor. Follow-up imaging consisting of DCE-MRI, CT and PET–CT were also performed approximately 1, 3 and 6 months after the last TACE. Follow up imaging will continue every 2-3 months for up to 4 years. Percent deposition of Lipiodol in the targeted tumor was assessed using 3D quantitative analysis on the 24hr post-TACE CT. Tumor response using RECIST, EASL, modified RECIST, tumor volume (volumetric RECIST), and volumetric tumor enhancement (quantitative EASL) were performed on the DCE-MRI, CT, and PET-CT, and correlated with Lipiodol deposition. Spearman rank correlation coefficient and Pearson’s product-moment correlation were used. The Kaplan-Meier method with the log-rank test was used to assess whether Lipiodol is a biomarker of survival. 12/30 patients with HCC and 12/30 patients with hepatic metastases have been enrolled (#NCT01877187). Clinical trial information: NCT01877187.
Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by KRAS Exon2 status.
Authors: Takenori Takahata, Satoshi Yuki, Hiroshi Nakatsumi, Kazuaki Harada, Hiraku Fukushima, Atsushi Sato, Takashi Kato, Takashi Meguro, Michio Nakamura, Nobuyuki Ehira, Ichiro Iwanaga, Miki Tateyama, Kazuteru Hatanaka, Kazunori Eto, Hiroyuki Okuda, Yoshimitsu Kobayashi, Osamu Muto, Masakazu Abe, Yuh Sakata, Yoshito Komatsu
Journal: Journal of Clinical Oncology (2015)

782 Background: A few reports have shown the efficacy of bevacizumab (BV) independent of the KRAS Exon2 mutational status (KRAS). We performed a sub-group analysis by KRAS from the HGCSG0802 observational cohort study with investigated 115 patients (pts) treated with first line BV for metastatic colorectal cancer (mCRC). Methods: The objective of HGCSG0802 was to evaluate progression-free survival (PFS), overall survival (OS), time to treatment-failure (TTF), response rate (RR), safety, etc. The key eligibility criteria were with evaluable lesions, older than 20 years, ECOG PS 0-2. In this analysis, pts characteristics, RR and safety were compared using Fisher’s exact test. Univariate and multivariate analysis for PFS were performed using patient characteristics. Survival analyses were performed with Kaplan-Meier method, log-rank test, and Cox proportional hazards model. Results: Of 108 pts (the full analysis set), 98 pts were evaluable for KRAS. Sixty-one pts (62.2%) had KRAS wild-type (wt) and 37 pts (37.8%) had mutation (mt). The pts characteristics between those with wt and with mt were generally balanced except for PS 0 (91.8% in wt, 75.7% in mt; p=0.037) and lung metastasis (34.4% in wt, 62.2% in mt; p=0.012).The median TTF was 7.4 months in wt versus 6.6 months in mt, and RR was 69.5% in wt versus 65.7% in mt. Adverse events related to BV were almost balanced except for bleeding (any grade) (31.1% in wt, 13.5% in mt; p=0.056).The median PFS was 9.9 months in wt versus 7.9 months in mt (HR=1.506; p=0.071). Although KRAS mt showed shorter PFS, there were not significant difference regardless of KRAS in Cox multivariate analysis (HR 1.314, 95% CI, 0.820-2.107, p=0.257). Conclusions: The HGCSG0802 could be a database to investigate first line BV for mCRC in clinical practice. Depending on the KRAS Exon2 mutational status, efficacy, and adverse events were no significant difference. We plan to conduct further follow up for survival, and to perform this analysis again.
A comparison of advanced pancreatic cancer patients treated on clinical trials with those from a SEER registry over an 18 year period
Authors: P. Jasti, B. F. El-Rayes, L. K. Heilbrun, P. A. Philip, M. M. Zalupski, A. F. Shields, R. Venkatramanamoorthy, R. Severson
Journal: Journal of Clinical Oncology (2008)

4628 Background: The Karmanos Cancer Institute (KCI) is an NCI-designated comprehensive cancer center located in Detroit. Over an 18 year period, 7 sequential phase II trials in advanced pancreatic cancer were conducted at KCI. The objective of this study was to explore the differences in outcome of patients treated on clinical trials versus standard of care, and to identify factors that influence selection of patients for clinical trials. A comparison of demographics, grade, and overall survival of patients treated on clinical trial vs. in an academic vs. community setting was undertaken. Methods: The target population was patients with advanced pancreatic adenocarcinoma diagnosed between 1/1/1986 and 12/31/2003. Demographics (age, race, gender, and socioeconomic status), stage, tumor grade, and survival were obtained from the Metropolitan Detroit SEER registry. Patients were divided into 3 mutually exclusive groups: treated on clinical trials (KCI- t), treated at KCI but not on a clinical trial (KCI), or treated at non-KCI institutions (N-KCI). Results: 9,040 patients met study criteria: 7,292 N-KCI, 1,643 KCI, and 105 KCI-t. A significant difference was observed across the 3 groups with respect to age (KCI-t lowest and N-KCI highest), race (African American (AA) patients represented 20%, 52% and 24% of N-KCI, KCI, and KCI-t patients, respectively), and grade. A significant difference in survival was observed based on age (< 60, median 5.5 mo. vs. > 60, 2.7 mo), race (AA 2.8 mo. vs. Caucasian, 3.4 mo), and grade (poorly differentiated, 3.6 mo vs. well differentiated, 7.6 mo). The median survival was higher in KCI-t (8.5 mo.; 95% CI 7.2–9.6) than in KCI (5.0 mo; 95% CI 4.5–5.5) or N-KCI (2.8 mo; 95% CI 2.7–3.0) Conclusions: Patients enrolled on our clinical trials were younger. AA's were under-represented on our clinical trials. Patients with advanced pancreatic cancer treated at academic institutions may have a better outcome than patients treated in a community setting. Clinical trials appear to offer a survival advantage for patients with advanced pancreatic cancer. No significant financial relationships to disclose.
Predictive factors associated with Gleason score underestimation on prostate biopsy in a monocentric cohort of 3,062 patients treated by mini-invasive radical prostatectomy.
Authors: Francois Audenet, Francois Rozet, Matthieu Resche-Rigon, Rémy Bernard, Daphne Lizee, Emeric Lacarriere, Dominique Prapotnich, Rafael Sanchez-Salas, Marc Galiano, Eric Barret, Xavier Cathelineau
Journal: Journal of Clinical Oncology (2014)

113 Background: Gleason score (GS) on prostate biopsy is a critical factor in the initial evaluation of patients with prostate cancer (PC), and can lead to different therapeutic options. However, it may differ from the final pathologic result on radical prostatectomy (RP) specimen in up to 30 to 50% of cases. The aim of this study was to explore the clinicopathological features and outcomes associated with Gleason upgrading from biopsy to RP in a contemporary cohort and to develop an upgrading risk tool available preoperatively. Methods: Using a monocentric prospectively maintained database, we included 3,062 patients who underwent minimally invasive RP between 2005 and 2012. All biopsies and surgical specimens were analyzed by dedicated pathologists. We explored clinicopathological features and outcomes associated with Gleason upgrading from biopsy to RP. A multivariate logistic regression was used to develop a nomogram predicting upgrading for Gleason 6 PC. Results: The median number of biopsy cores was 12 (10 to 13). The GS on biopsy was respectively 6, 7, and more than 7 in 58.5%, 37.4%, and 4.1%. The GS on biopsy was consistent with the specimen in 42.7%. The GS was upgraded in 37.8% and the primary pattern was upgraded in 14.1%. Patients upgraded from biopsy Gleason 6 to Gleason 7 on RP had a longer time to biochemical recurrence than those with Gleason 7 on both biopsy and RP, but a shorter time to BCR than those who remained Gleason 6 on RP (p&lt;0,0001). On multivariate analysis, variables predicting upgrading for Gleason 6 PC were: age (p=0.0014), abnormal digital rectal examination (p&lt;0.0001), prostate-specific antigen density (p&lt;0.0001), percentage of positive cores (p&lt;0.0001) and body-mass index (p=0.037). A nomogram was generated and validated internally. Conclusions: Biopsy GS is misleading in one third of cases. Gleason upgrading from biopsy to PR seems to have consequences on the clinical outcomes. A nomogram using clinicopathological features can be useful to recognize the probability of upgrading in patients with Gleason 6 PC at initial evaluation. This could help to better choose therapeutic options in low-risk PC.
Survival trends among patients with advanced hepatocellular carcinoma in the United States.
Authors: Krishna Bilas Ghimire, Binay Kumar Shah, Barsha Nepal
Journal: Journal of Clinical Oncology (2013)

329 Background: Sorafenib was approved by FDA for treatment of HCC in 2007. This study was conducted to evaluate survival outcome in advanced HCC during 2005-2006 and 2008-2009 using U.S. Surveillance, Epidemiology, and End Results (SEER) cancer registry database.Methods: We analyzed the Surveillance, Epidemiology, and End Results (SEER*Stat) database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub (1973-2009 varying) using MP-SIR session. We analysed 1 year relative survival rates among stage IV HCC patients between pre- sorafenib (2005- 2006) and post- sorafenib (2008- 2009) eras. We used seer Z test to compare relative survival rates among cohorts of patients categorized by gender and age groups (&lt;50 and &gt;50 years). Results: There were 2,497 (1,180 in pre-sorafenib era and 1,317 in post-sorafenib era) stage IV HCC patients reported in seer database. Overall 1 year relative survival rates ± standard error (SE) were: 12.5±0.7% (12.5±1% in pre sorafenib era vs 13.1±1.1% in post sorafenib era, Z score= 0.481, p value=0.63). Overall Relative survival rates among men and women were 12.9±0.8% (12.7±1.1% in pre vs 13.4±1.2 in post sorafenib era, Z score=0.254, p value=0.79) and 11.8±1.6% (11.7±2.2% in pre vs 11.5±2.5 post sorafenib era, Z score=0.469, p value=0.63) respectively. There was no significant differences between 1 year relative survival rates by age groups (&lt;50 and &gt;50 years). Conclusions: This study showed no significant difference in 1-year relative survival rates during 2008-2009 as compared to 2005-2006. More studies are required to find out why the findings of SHARP trial have not translated to population-based settings.[Table: see text]
Decreasing length of hospital stay following radical cystectomy using multimodal enhanced recovery protocol.
Authors: Hooman Djaladat, Hamed Ahmadi, Anne Schuckman, Siamak Daneshmand
Journal: Journal of Clinical Oncology (2014)

313 Background: To evaluate a peri-operative protocol to expedite recovery and decrease length of stay (LOS) without increasing readmission and complication rates after cystectomy for bladder cancer. Methods: From 5/2012 to 8/2013, a peri-operative protocol used in 126 unselected consecutive patients who underwent open cystectomy for bladder cancer with prospective follow-up. The enhanced recovery after surgery (ERAS) protocol focused on avoiding bowel prep and NGT, early feeding, minimizing narcotics and use of a μ-opioid antagonist. Exclusion was any adjunct surgery (10), previous diversion (2) and prolonged intubation (4). Time to bowel movement (BM) and regular diet, LOS, 30-day readmission and complication rates were captured. The outcomes of interest were compared to a historical cohort. Results: A total of 110 (84 male) patients were included. Median age was 69 y/o (range, 31-90). 40 (36%) patients were ≥ 75 y/o and 75 (68%) patients underwent continent diversion. 90 (82%) patients had BM and 87 (79%) were advanced to regular diet by postop day (POD) 2. Median LOS was 4 days and 63/110 (57%) discharged at or before POD 4. Five patients needed NGT due to ileus. Most common 30-day complications were anemia requiring transfusion (19%), UTI (13%) and dehydration (9%), with the latter two also being the most common etiologies for readmission. Major complications (≥ Clavian grade III) were seen in 15 (13%) patients and were significantly higher in patients ≥75 y/o than younger (22% vs. 8%; P=0.05). There was no difference in other measured outcomes with respect to age (≥75 vs. &lt;75 y/o) and type of diversion (continent vs. incontinent). Conclusions: Our current ERAS protocol resulted in significant reduction in time to BM and LOS without increasing early readmission and complication rates. [Table: see text]
Erratum: Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes
Authors: M M Patnaik, E Padron, R R LaBorde, T L Lasho, C M Finke, C A Hanson, J M Hodnefield, R A Knudson, R P Ketterling, A Al-kali, A Pardanani, N A Ali, R S Komrokji, A Tefferi
Journal: Leukemia (2013)